-
Eastman Releases Fourth Quarter and Full Year 2021 Financial Results
Time of Update: 2023-01-26
Specialty Materials –EBIT growth was driven by improved product mix and higher sales volumes, but higher raw material, energy and distribution costs outweighed higher selling prices, compressing spreads and having some adverse impact .
-
Raw materials up to 10,000! 4 consecutive rounds in a week! Many places announced the cancellation of control and the resumption of production and operation! Dozens of chemical raw materials rush high
Time of Update: 2023-01-01
com" style="margin: 0px; padding: 0px; outline: 0px; max-width: 100%; box-sizing: border-box; overflow-wrap: break-word; ">Source: Waterborne Big PlatformAfter 4 consecutive rounds of rise, global gas prices climbed collectivelyGlobal natural gas prices continue to rise as temperatures continue to drop, resulting in strong demand for natural gas.
-
Announcement of the State Food and Drug Administration on the issuance of the list of prohibitions on online sales of drugs (first edition
Time of Update: 2022-12-30
This is hereby announced.
This is hereby announced.
This is hereby announced.
This is hereby announced.
This is hereby announced.
-
Americhem increases investment in medical modified plastics in China
Time of Update: 2022-12-29
" ”Americhem's Medical Modified Materials business focuses on helping medical device manufacturers meet and optimize product performance and provide innovative material solutions.
" ”Americhem's Medical Modified Materials business focuses on helping medical device manufacturers meet and optimize product performance and provide innovative material solutions.
-
State Food and Drug Administration: Solidly promote the landing and production of key foreign-funded pharmaceutical projects
Time of Update: 2022-11-26
drugsmedical devicesforeign-funded pharmaceutical First, in accordance with the requirements of the relevant notice on strengthening the service work of foreign-funded enterprises, we will continue to promote the implementation of various work and achieve results.
-
The traditional Chinese medicine sector soared! Many stocks such as Jinling Pharmaceutical and Teyi Pharmaceutical closed with a high limit
Time of Update: 2022-11-26
The reasons for the price limit of Teyi Pharmaceutical include: the company focuses on characteristic Chinese medicines, has a characteristic Chinese patent medicine type of cough suppressant tablets for cold cough, and has successively acquired Hainan Haili and Guangdong Guoyitang Drugs (approved assets), and added many varieties such as skin disease blood poison pills and hypoglycemic pills.
-
The first polypropylene plant of Yanshan Petrochemical achieved a breakthrough in production excellence
Time of Update: 2022-11-05
Recently, Yanshan Petrochemical's No. 1 polypropylene unit achieved a cumulative excellent +1 grade rate of 95.
76% in the first half of the year, reaching the best level in five years Recently, Yanshan Petrochemical's No. 1 polypropylene unit achieved a cumulative excellent +1 grade rate of 95.
-
Cater to the market
Time of Update: 2022-11-04
It is guaranteed that each link has status confirmation and technical support from the adjustment of the powder melt index, the adjustment of the parameters of the extruder to the switching of the product silo Faced with the large span of melting index and high viscosity of the new product, which is prone to lumps, and the production technology process is complicated, it is easy to cause problems such as the shutdown of the extruder.
-
Let the world hear the voice of Chinese scholars: Professor Zhang Yonghong led the team to break through innovation and promote the continuous development of the field of refractory relapsed lymphoma
Time of Update: 2022-11-01
*For medical professionals onlyOn October 20-23, 2022, the 7th International Symposium on Childhood, Adolescent and Young Adult (CAYA) Non-Hodgkin Lymphoma was held in New York, USA. Recent scientific
-
Keyue Pharmaceutical announced that the application for a Phase II clinical trial of KP104 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) has been approved by the National Medical
Time of Update: 2022-10-31
Keyue Pharmaceutical, a global biotechnology company dedicated to the development of a new generation of complement drugs for the treatment of immune-mediated diseases, today announced that the China National Medical Products Administration (NMPA) has approved its Application for New Drug Application (CTA) for its Phase II clinical trial of KP104 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
-
Is there a difference between men and women at AFib risk? New research suggests that atrial fibrillation risk is associated with height
Time of Update: 2022-09-06
This traditional view is challenged by a new study from the Smidt Heart Institute, which shows that women have a 50 percent higher risk of developing abnormal arrhythmias than men if height is taken into account.
-
Collagen products trigger the "face value economy
Time of Update: 2022-09-03
In recent years, the "appearance economy" and "health economy" have shown a trend of younger consumption, and functional foods with collagen peptides as the main product that have the effect of beauty and skin have gradually become the new favorite in the market .
-
Shijiazhuang Refinery successfully produced melt index 400 polypropylene meltblown base material
Time of Update: 2022-08-22
The polypropylene has no plasticizer and high melt index, so the subsequent processing is more economical and environmentally friendly The success of this emergency production of Shilian has provided technical support for the in-depth development and application of Sinopec's third-generation loop pipe process technology.
-
Xinmai Medical has invested heavily in the research and development of innovative products for the treatment of major diseases in the respiratory field
Time of Update: 2022-08-20
(Suzhou) ("Xinmai Medical"), which focuses on subversive and innovative interventional devices for the treatment of major diseases in the cardiovascular and respiratory fields, With two "innovative medical device" products, and is expected to be approved for the market in 2023 for its renal nerve mapping/selective ablation system for the treatment of hypertension, it will fully promote transbronchoscopy for the treatment of early-stage lung tumors The development process of Precisely Controlled, Hypertonic Solution Assisted RF System .
-
HBM︱Region-based spatial standardization method of brain MRI images to achieve accurate registration of brain regions
Time of Update: 2022-06-02
(Credit: He H & Razlighi Q, Human Brain Mapping, 2022) The researchers also used functional MRI data to evaluate the spatially normalized results of the LG-RBSN .
